You are here

  • Home
  • Archive
  • Volume 33, Issue 5
  • Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (…

Article metrics

Article menu
Download PDFPDF
Original research
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311)

 

Online download statistics by month:

Online download statistics by month: March 2023 to April 2024

AbstractFullPdf
Mar 202316662
Apr 20234893229
May 20238855132
Jun 20233051614
Jul 202315865
Aug 202316667
Sep 2023312119
Oct 20237822
Nov 202310522
Dec 202316421
Jan 2024816340
Feb 202417365
Mar 202415432
Apr 20246753
Total3303211153